{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T14:17:33Z","timestamp":1779891453707,"version":"3.53.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-28252-7","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T13:30:28Z","timestamp":1766583028000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Two-year outcomes of denosumab treatment for osteoporosis comparing the effects of calcium and vitamin D supplementation"],"prefix":"10.1038","volume":"15","author":[{"given":"Young-Ho","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong-Eun","family":"Byun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwan-Hee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"key":"28252_CR1","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature01658","volume":"423","author":"WJ Boyle","year":"2003","unstructured":"Boyle, W. J., Simonet, W. S. & Lacey, D. L. Osteoclast differentiation and activation. Nature 423, 337\u2013342 (2003).","journal-title":"Nature"},{"key":"28252_CR2","doi-asserted-by":"publisher","first-page":"5050","DOI":"10.1210\/endo.142.12.8536","volume":"142","author":"S Khosla","year":"2001","unstructured":"Khosla, S. Minireview: The OPG\/RANKL\/RANK system. Endocrinology 142, 5050\u20135055 (2001).","journal-title":"Endocrinology"},{"key":"28252_CR3","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","volume":"89","author":"WS Simonet","year":"1997","unstructured":"Simonet, W. S. et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89, 309\u2013319 (1997).","journal-title":"Cell"},{"key":"28252_CR4","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1359\/JBMR.040305","volume":"19","author":"PJ Bekker","year":"2004","unstructured":"Bekker, P. J. et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J. Bone Miner. Res. 19, 1059\u20131066 (2004).","journal-title":"J. Bone Miner. Res."},{"key":"28252_CR5","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1056\/NEJMoa044459","volume":"354","author":"MR McClung","year":"2006","unstructured":"McClung, M. R. et al. Denosumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. 354, 821\u2013831 (2006).","journal-title":"N. Engl. J. Med."},{"key":"28252_CR6","doi-asserted-by":"publisher","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","volume":"85","author":"DM Black","year":"2000","unstructured":"Black, D. M. et al. Fracture risk reduction with alendronate in women with osteoporosis: The fracture intervention. Trial FIT Research Group. J. Clin. Endocrinol. Metab. 85, 4118\u20134124 (2000).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"28252_CR7","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s001980050010","volume":"11","author":"J Reginster","year":"2000","unstructured":"Reginster, J. et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral efficacy with risedronate therapy (VERT) study group. Osteoporos. Int. 11, 83\u201391 (2000).","journal-title":"Osteoporos. Int."},{"key":"28252_CR8","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1359\/JBMR.040325","volume":"19","author":"CH Chesnut 3rd","year":"2004","unstructured":"Chesnut, C. H. 3rd. et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J. Bone Miner. Res. 19, 1241\u20131249 (2004).","journal-title":"J. Bone Miner. Res."},{"key":"28252_CR9","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black, D. M. et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med. 356, 1809\u20131822 (2007).","journal-title":"N. Engl. J. Med."},{"key":"28252_CR10","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone, H. G. et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 5, 513\u2013523 (2017).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"28252_CR11","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1185\/030079907X188035","volume":"23","author":"S Bonnick","year":"2007","unstructured":"Bonnick, S. et al. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density. Curr. Med. Res. Opin. 23, 1341\u20131349 (2007).","journal-title":"Curr. Med. Res. Opin."},{"key":"28252_CR12","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/S0140-6736(80)92592-1","volume":"2","author":"R Lindsay","year":"1980","unstructured":"Lindsay, R., Hart, D. M., Forrest, C. & Baird, C. Prevention of spinal osteoporosis in oophorectomised women. Lancet 2, 1151\u20131154 (1980).","journal-title":"Lancet"},{"key":"28252_CR13","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1001\/jama.290.13.1729","volume":"290","author":"JA Cauley","year":"2003","unstructured":"Cauley, J. A. et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: The Women\u2019s Health initiative randomized trial. JAMA 290, 1729\u20131738 (2003).","journal-title":"JAMA"},{"key":"28252_CR14","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1359\/jbmr.061008","volume":"22","author":"EV McCloskey","year":"2007","unstructured":"McCloskey, E. V. et al. Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study. J. Bone Miner. Res. 22, 135\u2013141 (2007).","journal-title":"J. Bone Miner. Res."},{"key":"28252_CR15","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1808082","volume":"379","author":"IR Reid","year":"2018","unstructured":"Reid, I. R. et al. Fracture prevention with zoledronate in older women with osteopenia. N. Engl. J. Med. 379, 2407\u20132416 (2018).","journal-title":"N. Engl. J. Med."},{"key":"28252_CR16","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1056\/NEJMoa2407031","volume":"392","author":"MJ Bolland","year":"2025","unstructured":"Bolland, M. J. et al. Fracture prevention with infrequent zoledronate in women 50 to 60 years of age. N. Engl. J. Med. 392, 239\u2013248 (2025).","journal-title":"N. Engl. J. Med."},{"key":"28252_CR17","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s00198-004-1677-3","volume":"15","author":"EM Lewiecki","year":"2004","unstructured":"Lewiecki, E. M. et al. Special report on the official positions of the International Society for Clinical Densitometry. Osteoporos. Int. 15, 779\u2013784 (2004).","journal-title":"Osteoporos. Int."},{"key":"28252_CR18","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black, D. M. et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348, 1535\u20131541 (1996).","journal-title":"Lancet"},{"key":"28252_CR19","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","volume":"62","author":"SL Ruggiero","year":"2004","unstructured":"Ruggiero, S. L., Mehrotra, B., Rosenberg, T. J. & Engroff, S. L. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J. Oral Maxillofac. Surg. 62, 527\u2013534 (2004).","journal-title":"J. Oral Maxillofac. Surg."},{"key":"28252_CR20","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1210\/jc.2004-0952","volume":"90","author":"CV Odvina","year":"2005","unstructured":"Odvina, C. V. et al. Severely suppressed bone turnover: A potential complication of alendronate therapy. J. Clin. Endocrinol. Metab. 90, 1294\u20131301 (2005).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"28252_CR21","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1302\/0301-620X.89B3.18146","volume":"89","author":"SK Goh","year":"2007","unstructured":"Goh, S. K. et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: A caution. J. Bone Joint Surg. Br. 89, 349\u2013353 (2007).","journal-title":"J. Bone Joint Surg. Br."},{"key":"28252_CR22","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1210\/jc.2009-1947","volume":"95","author":"NB Watts","year":"2010","unstructured":"Watts, N. B. & Diab, D. L. Long-term use of bisphosphonates in osteoporosis. J. Clin. Endocrinol. Metab. 95, 1555\u20131565 (2010).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"28252_CR23","first-page":"62","volume":"36","author":"J-W Park","year":"2024","unstructured":"Park, J.-W., Yoo, J.-H., Lee, Y.-K., Park, J.-S. & Won, Y.-Y. Treatment of osteoporosis after hip fracture: Survey of the Korean Hip Society. H&P 36, 62\u201369 (2024).","journal-title":"H&P"},{"key":"28252_CR24","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1359\/jbmr.0809010","volume":"24","author":"JP Brown","year":"2009","unstructured":"Brown, J. P. et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: A randomized, blinded, phase 3 trial. J. Bone Miner. Res. 24, 153\u2013161 (2009).","journal-title":"J. Bone Miner. Res."},{"key":"28252_CR25","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.bone.2013.10.006","volume":"58","author":"C Roux","year":"2014","unstructured":"Roux, C. et al. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: Efficacy and safety results from a randomized open-label study. Bone 58, 48\u201354 (2014).","journal-title":"Bone"},{"key":"28252_CR26","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1097\/AOG.0b013e318291718c","volume":"121","author":"C Recknor","year":"2013","unstructured":"Recknor, C. et al. Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: A randomized open-label trial. Obstet. Gynecol. 121, 1291\u20131299 (2013).","journal-title":"Obstet. Gynecol."},{"key":"28252_CR27","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1210\/jc.2016-1801","volume":"101","author":"PD Miller","year":"2016","unstructured":"Miller, P. D. et al. Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates. J. Clin. Endocrinol. Metab. 101, 3163\u20133170 (2016).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"28252_CR28","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.17789","volume":"2","author":"P Yao","year":"2019","unstructured":"Yao, P. et al. Vitamin D and calcium for the prevention of fracture: A systematic review and meta-analysis. JAMA Netw. Open 2, e1917789 (2019).","journal-title":"JAMA Netw. Open"},{"key":"28252_CR29","doi-asserted-by":"publisher","first-page":"21","DOI":"10.11005\/jbm.2014.21.1.21","volume":"21","author":"IR Reid","year":"2014","unstructured":"Reid, I. R. Should we prescribe calcium supplements for osteoporosis prevention?. J. Bone Metab. 21, 21\u201328 (2014).","journal-title":"J. Bone Metab."},{"key":"28252_CR30","doi-asserted-by":"publisher","first-page":"139","DOI":"10.11005\/jbm.2012.19.2.139","volume":"19","author":"WS Do","year":"2012","unstructured":"Do, W. S. et al. Bisphosphonate-induced severe hypocalcemia\u2014A case report. J. Bone Metab. 19, 139\u2013145 (2012).","journal-title":"J. Bone Metab."},{"key":"28252_CR31","volume":"15","author":"S Dadana","year":"2023","unstructured":"Dadana, S., Gundepalli, S. & Kondapalli, A. Severe refractory hypocalcemia caused by denosumab. Cureus 15, e39866 (2023).","journal-title":"Cureus"},{"key":"28252_CR32","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1089\/jwh.2005.14.180","volume":"14","author":"JA Sunyecz","year":"2005","unstructured":"Sunyecz, J. A. & Weisman, S. M. The role of calcium in osteoporosis drug therapy. J. Womens Health (Larchmt) 14, 180\u2013192 (2005).","journal-title":"J. Womens Health (Larchmt)"},{"key":"28252_CR33","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3803\/EnM.2022.1427","volume":"37","author":"Y Rhee","year":"2022","unstructured":"Rhee, Y. et al. Real-world safety and effectiveness of denosumab in patients with osteoporosis: A prospective, observational study in South Korea. Endocrinol. Metab. (Seoul) 37, 497\u2013505 (2022).","journal-title":"Endocrinol. Metab. (Seoul)"},{"key":"28252_CR34","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2147\/TCRM.S24239","volume":"8","author":"AD Anastasilakis","year":"2012","unstructured":"Anastasilakis, A. D., Toulis, K. A., Polyzos, S. A., Anastasilakis, C. D. & Makras, P. Long-term treatment of osteoporosis: Safety and efficacy appraisal of denosumab. Ther. Clin. Risk Manag. 8, 295\u2013306 (2012).","journal-title":"Ther. Clin. Risk Manag."},{"key":"28252_CR35","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.2147\/TCRM.S123172","volume":"12","author":"K Ishikawa","year":"2016","unstructured":"Ishikawa, K. et al. High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis. Ther. Clin. Risk Manag. 12, 1831\u20131840 (2016).","journal-title":"Ther. Clin. Risk Manag."},{"key":"28252_CR36","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1002\/jbmr.1613","volume":"27","author":"GA Block","year":"2012","unstructured":"Block, G. A., Bone, H. G., Fang, L., Lee, E. & Padhi, D. A single-dose study of denosumab in patients with various degrees of renal impairment. J. Bone Miner. Res. 27, 1471\u20131479 (2012).","journal-title":"J. Bone Miner. Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-28252-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-28252-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-28252-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:08:00Z","timestamp":1777388880000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-28252-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["28252"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-28252-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]},"assertion":[{"value":"19 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Institutional Review Board (IRB) of Daegu Fatima Hospital (IRB No. DFH 2024-11-002), and all methods were performed in accordance with relevant guidelines and regulations, including the Declaration of Helsinki. The requirement for informed consent was waived by the IRB due to the retrospective nature of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"44588"}}